• Mashup Score: 3
    Cycle for Survival: The Movement to Beat Rare Cancers - 1 year(s) ago

    BEAT RARE CANCERS Support rare cancer research at Memorial Sloan Kettering Cancer Center. 100% of every dollar raised funds innovative research and lifesaving clinical trials.

    Source: secure2.convio.net
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of rosslevinemd
      rosslevinemd

      Everyone, it is time to think about Cycle for Survival at @MSKCancerCenter All donations->1M total before end of the year will be MATCHED! Please consider supporting this amazing cause and our team!!!! https://t.co/29zRl5k3WH

  • Mashup Score: 3
    Ajax Therapeutics Appoints Srdan “Serge” Verstovsek, MD, PhD, to Scientific Advisory Board - AJAX - 1 year(s) ago

    Dr. Verstovsek is a world-renowned expert in the treatment of myeloproliferative neoplasms New York, NY, December 6, 2022 – Ajax Therapeutics, Inc., a biopharmaceutical company applying computational chemistry and structure-based technologies to develop novel small molecules for myeloproliferative neoplasms (MPNs), today announced the appointment of Srdan “Serge” Verstovsek, MD, PhD, to the…

    Source: AJAX
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of rosslevinemd
      rosslevinemd

      Welcome Serge! Ajax Therapeutics Appoints Srdan “Serge” Verstovsek, MD, PhD, to Scientific Advisory Board - AJAX https://t.co/Ib4C9Ca4Jq

  • Mashup Score: 20
    Single cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia - 2 year(s) ago

    Measurable residual disease (MRD), defined as the population of cancer cells which persists following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia (AML) and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual…

    Source: bioRxiv
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of rosslevinemd
      rosslevinemd

      Pre-print time! Happy to share our exciting study on single cell DNA+protein seq MRD assay in AML. A great collaboration between @RossLevine Lab @MSKPathology @CHM_MSKCC and @MissionBio teams! (COI: I am on Mission Bio SAB). @drwenbin_xiao led this work! https://t.co/twaBGHY0SE

  • Mashup Score: 2
    Jon Stewart Deep Dish Rant - 2 year(s) ago

    If you saw the the video on my old channel it got removed. But I am determined to keep it alive, so here it is re uploaded once again.

    Source: YouTube
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of rosslevinemd
      rosslevinemd

      ⁦@ElfLabUChicago⁩ somehow this made me think of you… https://t.co/FuBUgTJjLl

  • Mashup Score: 5
    Research Specialist B (Cancer Biology - Business Office) - 2 year(s) ago

    University Overview The University of Pennsylvania, the largest private employer in Philadelphia, is a world-renowned leader in education, research, and innovation. This historic, Ivy League school consistently ranks among the top 10 universities in the annual U.S. News & World Report survey. Penn has 12 highly-regarded schools that provide opportunities for undergraduate, graduate and continuing…

    Source: wd1.myworkdaysite.com
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of rosslevinemd
      rosslevinemd

      RT @bowman_rl: Job description and application are live here! https://t.co/vmRZ30zXUH Looking for a first lab member. Let’s build somethi…

  • Mashup Score: 4
    Jak2V617F Reversible Activation Shows an Essential Requirement for Jak2V617F in Myeloproliferative Neoplasms - 2 year(s) ago

    Janus kinases (JAKs) mediate cytokine signaling, cell growth and hematopoietic differentiation.1 Gain-of-function mutations activating JAK2 signaling are seen in the majority of myeloproliferative neoplasm (MPN) patients, most commonly due to the JAK2V617F driver allele.2 While clinically-approved JAK inhibitors improve symptoms and outcomes in MPNs, remissions are rare, and mutant allele burden…

    Source: bioRxiv
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of rosslevinemd
      rosslevinemd

      Part 2 of the GOLDI-lox preprint set, led by @andrewdunbar_md and @bowman_rl. Q: If you had a system which can test oncogenic dependency in context of co-mutant disease alleles, what question would you ask? For us, it was simple; JAK2V617F! #mpnsm https://t.co/g0lXCpJI6l

  • Mashup Score: 1
    Integrated Single-Cell Genotyping and Chromatin Accessibility Charts JAK2V617F Human Hematopoietic Differentiation - 2 year(s) ago

    In normal somatic tissue differentiation, changes in chromatin accessibility govern priming and commitment of precursors towards cellular fates. In turn, somatic mutations can disrupt differentiation topologies leading to abnormal clonal outgrowth. However, defining the impact of somatic mutations on the epigenome in human samples is challenging due to admixed mutated and wildtype cells. To chart…

    Source: bioRxiv
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of rosslevinemd
      rosslevinemd

      They then used the JAK2V617F-GL system to perform transcriptional/epigenetic profiling of JAK2V617F mutant HSPCs. Key targets/pathways reversibly activated by JAK2V617F in vivo matched up beautifully with the human sc study by @danlandau! So cool! https://t.co/2PSkwTKdcD

Load More